Wai Yuen Tong Medicine Holdings (HKSE:00897) COGS-to-Revenue : 0.52 (As of Sep. 2023)

View and export this data going back to 1997. Start your Free Trial

What is Wai Yuen Tong Medicine Holdings COGS-to-Revenue?

Wai Yuen Tong Medicine Holdings's Cost of Goods Sold for the six months ended in Sep. 2023 was HK$355 Mil. Its Revenue for the six months ended in Sep. 2023 was HK$679 Mil.

Wai Yuen Tong Medicine Holdings's COGS to Revenue for the six months ended in Sep. 2023 was 0.52.

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin. Wai Yuen Tong Medicine Holdings's Gross Margin % for the six months ended in Sep. 2023 was 47.73%.

Wai Yuen Tong Medicine Holdings COGS-to-Revenue Historical Data

The historical data trend for Wai Yuen Tong Medicine Holdings's COGS-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Wai Yuen Tong Medicine Holdings COGS-to-Revenue Chart

Wai Yuen Tong Medicine Holdings Annual Data

Trend

Mar14

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

COGS-to-Revenue

Get a 7-Day Free Trial

0.60

0.55

0.60

0.59

0.52

Wai Yuen Tong Medicine Holdings Semi-Annual Data
	Mar14	Sep14	Mar15	Sep15	Mar16	Sep16	Mar17	Sep17	Mar18	Sep18	Mar19	Sep19	Mar20	Sep20	Mar21	Sep21	Mar22	Sep22	Mar23	Sep23
COGS-to-Revenue	Get a 7-Day Free Trial															0.58	0.60	0.56	0.49	0.52

Wai Yuen Tong Medicine Holdings COGS-to-Revenue Calculation

Wai Yuen Tong Medicine Holdings's COGS to Revenue for the fiscal year that ended in Mar. 2023 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	674.651	/	1286.428
	=	0.52

Wai Yuen Tong Medicine Holdings's COGS to Revenue for the quarter that ended in Sep. 2023 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	354.777	/	678.804
	=	0.52

Wai Yuen Tong Medicine Holdings (HKSE:00897) COGS-to-Revenue Explanation

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin.

Wai Yuen Tong Medicine Holdings's Gross Margin % for the six months ended in Sep. 2023 is calculated as:

Gross Margin %	=	1	-	COGS to Revenue
	=	1	-	Cost of Goods Sold / Revenue
	=	1	-	354.777 / 678.804
	=	47.73 %

A company that has a moat can usually maintain or even expand their Gross Margin. A company can increase its Gross Margin in two ways. It can increase the prices of the goods it sells and keeps its Cost of Goods Sold unchanged. Or it can keep the sales price unchanged and squeeze its suppliers to reduce the Cost of Goods Sold. Warren Buffett believes businesses with the power to raise prices have moats.

Wai Yuen Tong Medicine Holdings COGS-to-Revenue Related Terms

Thank you for viewing the detailed overview of Wai Yuen Tong Medicine Holdings's COGS-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Wai Yuen Tong Medicine Holdings (HKSE:00897) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Wai Yuen Tong Medicine Holdings Ltd (HKSE:00897) » Definitions » COGS-to-Revenue

Traded in Other Exchanges

N/A

Address

39 Wang Kwong Road, Suite 3101, 31st Floor, Skyline Tower, Kowloon Bay, Kowloon, Hong Kong, HKG

Website

https://www.wyth.net

Wai Yuen Tong Medicine Holdings Ltd is an investment holding company. The company's operating segment includes production and sale of Chinese pharmaceutical and health food products; production and sale of Western pharmaceutical and health food products and property investment and management and sale of properties in the agricultural produce market. It generates maximum revenue from the production and sale of Chinese pharmaceutical and health food products which include manufacturing, processing, and sale of traditional Chinese medicine which includes Chinese medicinal products sold under the brand name Wai Yuen Tong. Geographically, it derives a majority of revenue from Mainland China.

Executives

Wang On Group Limited	2501 Other
Tang Ching Ho	2501 Other
Yau Yuk Yin	2202 Interest of your spouse

Wai Yuen Tong Medicine Holdings (HKSE:00897) Headlines

No Headlines